FindTrial
Sign In

Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma

Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-022180-35-DE
Enrollment
Unknown
Registered
2011-01-18
Start date
2011-03-29
Completion date
Unknown
Last updated
2015-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed nodular lymphocyte predominat Hodgkin Lymphoma MedDRA version: 12.1 Level: LLT Classification code 10020227 Term: Hodgkin's disease lymphocyte predominance type recurrent

Interventions

Trade Name: Arzerra Product Name: Ofatumumab Product Code: Ofatumumab Pharmaceutical Form: Solution for infusion INN or Proposed INN: OFATUMUMAB CAS Number: 679818-59-8 Current Sponsor code: ofatumuma

Sponsors

University of Cologne
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Germany

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026